BeOne Medicines (ONC) Invested Capital (2015 - 2026)

BeOne Medicines (ONC) has reported Invested Capital for 12 consecutive years, with $6.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital rose 32.21% year-over-year to $6.2 billion in Q2 2026; TTM through Jun 2026 was $6.2 billion, a 32.21% increase from a year earlier, with the FY2025 full-year figure at $5.4 billion, up 3.43% from the prior year.
• Invested Capital was $6.2 billion for Q2 2026 at BeOne Medicines, up from $5.8 billion in the prior quarter.
• Over five years, Invested Capital peaked at $6.6 billion in Q3 2025 and troughed at $4.3 billion in Q3 2023.
• A 5-year average of $5.1 billion and a median of $4.8 billion in 2022 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital declined 27.22% in 2023 and soared 46.83% in 2025, its largest moves.
• Over 5 years, Invested Capital stood at $4.9 billion in 2022, then decreased by 10.12% to $4.4 billion in 2023, then climbed by 17.6% to $5.2 billion in 2024, then gained by 3.43% to $5.4 billion in 2025, then climbed by 16.11% to $6.2 billion in 2026.
• The last three Invested Capital figures came in at $6.2 billion (Q2 2026), $5.8 billion (Q1 2026), and $5.4 billion (Q4 2025), per Business Quant data.